Pentavalent HIV-1 vaccine protects against simian-human immunodeficiency virus challenge

DSpace/Manakin Repository

Pentavalent HIV-1 vaccine protects against simian-human immunodeficiency virus challenge

Citable link to this page

 

 
Title: Pentavalent HIV-1 vaccine protects against simian-human immunodeficiency virus challenge
Author: Bradley, Todd; Pollara, Justin; Santra, Sampa; Vandergrift, Nathan; Pittala, Srivamshi; Bailey-Kellogg, Chris; Shen, Xiaoying; Parks, Robert; Goodman, Derrick; Eaton, Amanda; Balachandran, Harikrishnan; Mach, Linh V.; Saunders, Kevin O.; Weiner, Joshua A.; Scearce, Richard; Sutherland, Laura L.; Phogat, Sanjay; Tartaglia, Jim; Reed, Steven G.; Hu, Shiu-Lok; Theis, James F.; Pinter, Abraham; Montefiori, David C.; Kepler, Thomas B.; Peachman, Kristina K.; Rao, Mangala; Michael, Nelson L.; Suscovich, Todd J.; Alter, Galit; Ackerman, Margaret E.; Moody, M. Anthony; Liao, Hua-Xin; Tomaras, Georgia; Ferrari, Guido; Korber, Bette T.; Haynes, Barton F.

Note: Order does not necessarily reflect citation order of authors.

Citation: Bradley, T., J. Pollara, S. Santra, N. Vandergrift, S. Pittala, C. Bailey-Kellogg, X. Shen, et al. 2017. “Pentavalent HIV-1 vaccine protects against simian-human immunodeficiency virus challenge.” Nature Communications 8 (1): 15711. doi:10.1038/ncomms15711. http://dx.doi.org/10.1038/ncomms15711.
Full Text & Related Files:
Abstract: The RV144 Thai trial HIV-1 vaccine of recombinant poxvirus (ALVAC) and recombinant HIV-1 gp120 subtype B/subtype E (B/E) proteins demonstrated 31% vaccine efficacy. Here we design an ALVAC/Pentavalent B/E/E/E/E vaccine to increase the diversity of gp120 motifs in the immunogen to elicit a broader antibody response and enhance protection. We find that immunization of rhesus macaques with the pentavalent vaccine results in protection of 55% of pentavalent-vaccine-immunized macaques from simian–human immunodeficiency virus (SHIV) challenge. Systems serology of the antibody responses identifies plasma antibody binding to HIV-infected cells, peak ADCC antibody titres, NK cell-mediated ADCC and antibody-mediated activation of MIP-1β in NK cells as the four immunological parameters that best predict decreased infection risk that are improved by the pentavalent vaccine. Thus inclusion of additional gp120 immunogens to a pox-prime/protein boost regimen can augment antibody responses and enhance protection from a SHIV challenge in rhesus macaques.
Published Version: doi:10.1038/ncomms15711
Other Sources: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5472724/pdf/
Terms of Use: This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA
Citable link to this page: http://nrs.harvard.edu/urn-3:HUL.InstRepos:33490757
Downloads of this work:

Show full Dublin Core record

This item appears in the following Collection(s)

 
 

Search DASH


Advanced Search
 
 

Submitters